Novel transcript, antisense to CAMTA2 (ENSG00000234203)

Novel transcript, antisense to CAMTA2 (ENSG00000234203) is a naturally occurring non-coding RNA (natural antisense transcript, or NAT) with sequence complementary to the CAMTA2 gene. NATs regulate their sense (protein-coding) gene partners through several mechanisms, including: - Transcriptional interference (competition or blockage at the transcription level) - RNA masking (prevention of RNA processing/splicing) - Double-stranded RNA-dependent effects (leading to RNA degradation or gene silencing) - Chromatin remodeling and epigenetic silencing[1][3] NATs like the transcript antisense to CAMTA2 do not encode proteins and are typically not drug targets, receptors, enzymes, or similar therapeutic targets. Their roles are primarily in the regulation of gene expression at transcriptional and/or post-transcriptional levels[1][3]. Evaluation of Target Status: This entry does not describe a molecular target in the sense used for pharmacological intervention (i.e., not a receptor, transporter, enzyme, ion channel, or similar). It is listed in gene annotation databases but functions as a regulatory RNA. There is no evidence that this NAT is currently considered a therapeutic target, nor are there known drugs, disease biomarkers, or safety issues directly associated with it. Nature of the Target Entry: This appears as a database description for a transcript with antisense orientation to CAMTA2. This kind of database entry is necessary for annotation completeness, but it should not be considered a canonical molecular target for drug intervention. The entry is "incorrect" as a drug target due to the following: - It is a functional RNA, not a protein; - It lacks evidence of being a therapeutic target; - No disease links or drug interactions have been reported for this transcript[1][3].

Other names

Antisense to CAMTA2NAT to CAMTA2